Research programme: hyaluronic acid-based rheumatoid arthritis therapeutic - Anika Therapeutics/University of Massachusetts Amherst
Latest Information Update: 04 Aug 2015
At a glance
- Originator Anika Therapeutics; University of Massachusetts Amherst
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Rheumatoid arthritis
Most Recent Events
- 30 Jul 2015 Preclinical trials in Rheumatoid arthritis in USA (Parenteral)